***Background.*** Intravenous aminoglycoside (AG) dosing is complex and highly individualized based on indication, patient\'s age, and renal function. Protocols available at study site guide dosing of AGs. This study assesses adherence to current protocols and investigates efforts needed to optimize AG dosing.

***Methods.*** 100 consecutive patients who received AG (gentamicin, tobramycin, or amikacin) from July-August 2013 were included. Patients were excluded if AG given for peri-operative prophylaxis, non-TB mycobacterium, or received AG immediately prior to admission. Dosing was classified as optimal if in accordance with dosing protocols. Dosing weight included actual body weight, unless obese, then adjusted body weight was used. Peak, trough, and random levels and associated dose adjustments were assessed. AG-induced nephrotoxicity per RIFLE criteria was evaluated in patients receiving ≥5 days therapy.

***Results.*** Of 100 patients, 40% received gentamicin, 35% tobramycin, and 25% amikacin. 57% of orders occurred in an ICU setting. Most common infections were sepsis (50%), respiratory (16%), and intra-abdominal (9%). Median duration was 1 day (IQR 1-2.25). Majority of orders (48%) used traditional interval. Total of 62 orders were adherent to protocol for both dose and frequency. 35% of orders contained doses not according to protocol (14% of doses above and 21% of doses below protocol), while 2% contained non-protocol frequency and 1% contained frequency plus dose not according to protocol. 93% of doses higher than protocol were in obese patients. A total of 67 levels were ordered for 35 patients, with a majority (63%) being random levels. Of peak and trough levels, 38% and 65% were within therapeutic range. Dose adjustments occurred in 4 orders, 75% were deemed appropriate. Of 11 patients assessed for AG-induced nephrotoxicity, one (9%) met criteria. Thirty-three (68%) of 49 of traditional interval orders were eligible for extended interval dosing.

***Conclusion.*** More than one-third of AG orders were non-adherent to available protocols. Majority of orders higher than protocol occurred in obese patients. AG-induced nephrotoxicity was rare. Investigation of clinical decision support to optimize initial AG dosing to achieve PK-PD targets is warranted.
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